Loading…
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $58M | $-20M | $-34M | $-15M | 131.7% | 9.2% | 9.2% |
| 2024 | $53M | $-3M | $-31M | $-2M | -645.9% | 26.9% | 118.3% |
| 2023 | $42M | $-9M | $-14M | $-10M | -43.0% | 19.2% | -27.8% |
| 2022 | $35M | $-17M | $-20M | $-15M | -47.4% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 35.36 | 42.16 | 53.49 | 58.44 |
| Operating Revenue | - | 35.36 | 42.16 | 53.49 | 58.44 |
| Cost Of Revenue | - | 15.40 | 21.06 | 27.64 | 31.31 |
| Gross Profit | - | 19.95 | 21.11 | 25.85 | 27.12 |
| Operating Expense | - | 40.13 | 33.34 | 32.79 | 51.70 |
| Research And Development | - | 11.81 | 6.14 | 5.33 | 5.62 |
| Selling General And Administration | - | 27.17 | 26.10 | 26.49 | 45.16 |
| Total Expenses | - | 55.54 | 54.39 | 60.43 | 83.01 |
| Operating Income | - | -20.18 | -12.23 | -6.94 | -24.58 |
| Total Operating Income As Reported | - | -20.18 | -12.23 | -10.66 | -24.58 |
| EBITDA | - | -16.77 | -8.71 | -3 | -20.08 |
| Normalized EBITDA | - | -16.77 | -5.86 | 22.12 | -9.74 |
| EBIT | - | -20.18 | -12.23 | -6.94 | -24.58 |
| Interest Expense | 0 | - | - | - | - |
| Net Interest Income | 0 | - | - | - | - |
| Other Non Operating Income Expenses | - | 0.26 | 0.70 | 0.66 | 0.64 |
| Other Income Expense | - | 0.26 | -2.15 | -24.47 | -9.70 |
| Interest Expense Non Operating | 0 | - | - | - | - |
| Net Non Operating Interest Income Expense | 0 | - | - | - | - |
| Pretax Income | - | -19.91 | -14.38 | -31.40 | -34.28 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income From Continuing And Discontinued Operation | - | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income From Continuing Operation Net Minority Interest | - | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income | - | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income Common Stockholders | - | -19.91 | -14.38 | -31.40 | -34.28 |
| Net Income Including Noncontrolling Interests | - | -19.91 | -14.38 | -31.40 | -34.28 |
| Normalized Income | - | -19.91 | -11.53 | -6.28 | -23.94 |
| Diluted NI Availto Com Stockholders | - | -19.91 | -14.38 | -31.40 | -34.28 |
| Basic Average Shares | - | 10.16 | 10.97 | 11.52 | 11.96 |
| Diluted Average Shares | - | 10.16 | 10.97 | 11.52 | 11.96 |
| Reconciled Depreciation | - | 3.41 | 3.52 | 3.93 | 4.50 |
| Reconciled Cost Of Revenue | - | 13.14 | 18.64 | 24.68 | 27.73 |
| Total Unusual Items | - | - | -2.85 | -25.13 | -10.34 |
| Total Unusual Items Excluding Goodwill | - | - | -2.85 | -25.13 | -10.34 |
| Special Income Charges | - | - | 0 | -3.73 | 0 |
| Impairment Of Capital Assets | - | - | 0 | 3.73 | 0 |
| Gain On Sale Of Security | - | - | -2.85 | -21.40 | -10.34 |
| Depreciation Amortization Depletion Income Statement | - | 1.15 | 1.10 | 0.97 | 0.92 |
| Depreciation And Amortization In Income Statement | - | 1.15 | 1.10 | 0.97 | 0.92 |
| Amortization | - | 1.15 | 1.10 | 0.97 | 0.92 |
| Amortization Of Intangibles Income Statement | - | 1.15 | 1.10 | 0.97 | 0.92 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| LENSAR, Inc.this co. | LNSR | $68M | -1.98 | -2.61 | 131.7% | -2.88 |
| Outset Medical, Inc. | OM | $88M | -1.07 | 0.69 | -64.3% | -2.46 |
| Aardvark Therapeutics, Inc. | AARD | $86M | -1.49 | 0.81 | -54.0% | -0.63 |
| biote Corp. | BTMD | $84M | 3.10 | -1.43 | -46.2% | 3.25 |
| Pulmonx Corporation | LUNG | $68M | - | 1.26 |
| - |
| - |
| - |
| - |
| -99.8% |
| - |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M | -2.09 | 5.86 | -280.5% | - |
| Peer Median | - | -1.07 | 0.78 | -104.8% | -0.65 | |